Benzylfentanyl
 | |
| Names | |
|---|---|
| IUPAC name
N-(1-Benzylpiperidin-4-yl)-N-phenylpropanamide | |
| Identifiers | |
| 1474-02-8 | |
| 3D model (Jmol) | Interactive image |
| ChemSpider | 220920 |
| ECHA InfoCard | 100.014.559 |
| PubChem | 252141 |
| |
| |
| Properties | |
| C21H26N2O | |
| Molar mass | 322.45 g·mol−1 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Benzylfentanyl (R-4129) is a fentanyl analog.[1] It was temporarily placed in the US Schedule I by emergency scheduling in 1985 due to concerns about its potential for abuse as a designer drug, but this placement was allowed to expire and benzylfentanyl was formally removed from controlled substance listing in 2010, after the DEA's testing determined it to be "essentially inactive" as an opioid.[2] Benzylfentanyl has a Ki of 213nM at the mu opioid receptor, binding around 200x less strongly than fentanyl itself.[3]
Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[4]
References
- ↑ Ruangyuttikarn, W; Law, MY; Rollins, DE; Moody, DE (1990). "Detection of fentanyl and its analogs by enzyme-linked immunosorbent assay". Journal of analytical toxicology. 14 (3): 160–4. doi:10.1093/jat/14.3.160. PMID 2374405.
- ↑ Correction of Code of Federal Regulations: Removal of Temporary Listing of Benzylfentanyl and Thenylfentanyl as Controlled Substances
- ↑ Utilization of a radioreceptor assay for the analysis of fentanyl analogs in urine Mario Enrique Alburges
- ↑ Jane Mounteney; Isabelle Giraudon; Gleb Denissov; Paul Griffiths (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe.". The international journal of drug policy. 26 (7): 626–631. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.